PHESGO (PERTUZUMAB-TRASTUZUMAB)
    PRODUCT MONOGRAPH

    Plus chemotherapy for the neoadjuvant and adjuvant treatment of hER2-positive Early Breast Cancer (eBC) and for the first-line treatment of HER2-positive metastatic breast cancer (mBC)